Maximum quantity allowed is 999
请选择数量
CAS RN: 5536-17-4 | 产品编码: V0175
Vidarabine

技术规格
Appearance | White to Light yellow powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Purity(Nonaqueous Titration) | min. 98.0 % |
Specific rotation | -2.0 to -4.0 deg(C=1, DMF) |
NMR | confirm to structure |
物性(参考值)
熔点 | 257 °C |
最大吸收波长 | 260 nm (H__2O) |
GHS
相关法规
RTECS# | AU6200000 |
运输信息
HS编码* | 2934.99-000 |
应用
Vidarabine: An Arabinosyladenine with Ant-Virus and Anti-Cancer Activities
Vidarabine (arabinosyladenine, ara-A) is a synthetic purine nucleoside, and was first synthesized by Lee et al. in 1960. Vidarabine was originally intended as an anti-cancer agent, while the anti-viral activity against herpesvirus and vaccinia virus was reported by Rudder et al in 1965. And also the activity against varicella-zoster virus was reported by Miller et al. in 1968. Vidarabine had a broad-spectrum activity against DNA viruses but little activity against RNA viruses. Vidarabine is converted to the active form vidarabine triphosphate (ara-ATP) which inhibits viral DNA polymerase activity in vitro and in vivo. (The product is for research purpose only.)
References
- Potential Anticancer Agents.1 Xl. Synthesis of the β-Anomer of 9-(D-Arabinofuranosyl)-Adenine
- Inhibitory effect of some nucleosides on the growth of various human viruses in tissue culture.
- Antiviral activity of 9-beta-D-arabinofuranosyladenine. I. Cell culture studies.
- Inhibition of Herpesvirus DNA Synthesis by 9-β-D-Arabinofuranosyladenine in Cellular and Cell-Free Systems
- The mechanisms of lethal action of arabinosyl cytosine (araC) and arabinosyl adenine (araA)
- Vidarabine: a preliminary review of its pharmacological properties and therapeutic use
产品文档 (部分产品的分析图谱无法提供,敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助,请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注:该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉,您搜索的分析图谱无法提供。